Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Other Operating Expenses (2018 - 2025)

Historic Other Operating Expenses for 10x Genomics (TXG) over the last 6 years, with Q2 2025 value amounting to -$40.7 million.

  • 10x Genomics' Other Operating Expenses changed N/A to -$40.7 million in Q2 2025 from the same period last year, while for Dec 2025 it was -$49.9 million, marking a year-over-year change of. This contributed to the annual value of -$49.9 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q2 2025, 10x Genomics' Other Operating Expenses is -$40.7 million.
  • 10x Genomics' 5-year Other Operating Expenses high stood at $41.4 million for Q3 2023, and its period low was -$40.7 million during Q2 2025.
  • Its 3-year average for Other Operating Expenses is $1.7 million, with a median of -$330000.0 in 2021.
  • Data for 10x Genomics' Other Operating Expenses shows a peak YoY increase of 3708.61% (in 2021) and a maximum YoY decrease of 36397.52% (in 2021) over the last 5 years.
  • Over the past 3 years, 10x Genomics' Other Operating Expenses (Quarter) stood at -$850000.0 in 2021, then skyrocketed by 2403.29% to $19.6 million in 2023, then crashed by 307.89% to -$40.7 million in 2025.
  • Its Other Operating Expenses was -$40.7 million in Q2 2025, compared to -$9.2 million in Q1 2025 and $19.6 million in Q4 2023.